Respond to prefers-color-scheme dark in app web views

Follow section front redirects in Spectrum

Enable NLP source in PCS for load testing

Switch off the News Alerts Survey Widget when we have enough responses

Poll to determine if new LUF updates are available

Allows the winning A/B test variant to be turned on without Spectrum deployment

Show infinite scrolling sections in Assembler MultiView

Show option for NLP article summaries in Action Bar

A general feature flag for Recipe Features that aren't yet released

Feature flag for media team features that aren't yet released

Use new Orca video player for preroll plugin in Spectrum

Show the snow tracker (instead of the heat tracker) on Spectrum

You asked: Do I need a passport for my cruise?

What’s the best bus to New York? We tested 5 for comfort and value.

Adaptive equipment is making national parks more inclusive

On Press Freedom Day, little to celebrate for Hong Kong’s journalists

Young Georgians want to be part of Europe. Their government is in the way.

Taxes are inevitable. Paying to prepare them doesn’t have to be.

Is Pastis as good as our food critic thought? He sent spies to find out.

Trevor Williams’s escape act helps Nationals blank Rangers 

Nationals can’t solve Nate Eovaldi, drop series finale to Rangers

The dangerous new call for regime change in Beijing

Ukrainian men abroad voice anger over pressure to return home to fight 

U.K. local election results could spell doom for Conservative Party

Hope Hicks witnessed nearly every Trump scandal. Now she must testify.

Elections 2024 latest news: Biden to honor distinguished Americans; Trump back in N.Y. court

To the Gaza protesters helping to elect Trump: Give it a rest

Riot police and over 2,000 arrests: A look at 2 weeks of campus protests

Hope on the horizon | The Trump Trials: Sidebar

Police break into UCLA encampment

An I bond is now at 4.28 percent. Are they still a good deal?

Use these 6 points to say no to a college you and your kid can’t afford

How this new rule protects retirement savers from costly advice

The New York Times, alone in its outrage over access to Biden

Wait, what is Stephen A. Smith talking about? Find out with our quiz.

Stephen A. Smith would like even more of your attention

This is the technology we’re loving right now

NASA moon capsule suffered extensive damage during 2022 test flight

Microsoft is changing how you log in to your accounts

Teen grabs wheel when driver passes out and school bus veers into traffic

Cat climbed into Amazon return box, found alive 630 miles away

I learned to heal my sadness by cradling dying chickens 

Miss Manners: Host eats luxurious breakfast, leaves cereal for guest

Ask Amy: Should I be the best man if I think the bride is abusive?

Carolyn Hax: Husband keeps pushing modest spouse to wear sexier clothes

Allyson Welsch

After more than a decade studying a rare eye cancer that produces some of the hardest-to-fight tumors, researchers from University of Pittsburgh Medical Center have found a treatment that works on some patients and, more importantly, a tool that can predict when it is likely to succeed.

The work, published in <a href="https://www.nature.com/articles/s41467-024-46906-4" target=_blank>Nature Communications,</a> is  being validated in a clinical trial involving at least 30 patients. It could pave the way for similar methods designed to overcome one of the enduring frustrations of cancer care.

Because tumors differ, not only between patients but even inside the same patient, a treatment that works on one mass may fail on another, even when both are of the same cancer type.

The researchers in Pittsburgh tackled this problem in uveal melanoma, an eye cancer that afflicts only 5 people in a million, but that half the time spreads to other parts of the body, often the liver. The median survival once uveal melanoma has spread has been less than seven months, according to a <a href="https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2686116" target=_blank>2018 study</a> in the journal JAMA Ophthalmology.

“We chose this because it was one of the only cancers that 10 years ago when we started, there was nothing approved for it,” said Udai Kammula, who led the study and directs the Solid Tumor Cell Therapy Program at UPMC Hillman Cancer Center in Pittsburgh.

Scientists had long speculated that the reason uveal melanoma is so tough to fight is that something helps the tumor keep out T cells, a key part of the body’s immune system that develops in bone marrow. However, previous studies by Kammula and his colleagues showed that uveal melanoma tumors actually have T cells inside, and they are turned on.

The problem? The cells lie dormant instead of multiplying and reaching numbers large enough to overwhelm the tumor.

The culprit appears to reside somewhere inside the tumor’s ecosystem of cells, molecules and blood vessels, known formally as the tumor’s “microenvironment.” Kammula compares this ecosystem to the infrastructure that supports a city. Something in that infrastructure helps protect uveal melanoma tumors by preventing the critical T cells from multiplying.

“Ultimately, if we’re going to get rid of cancer, we have to get rid of this infrastructure,” Kammula said.

He and his colleagues have had some success using a treatment known as adoptive cell therapy, which was<a href="https://pubmed.ncbi.nlm.nih.gov/3264384/" target=_blank> developed</a> in the 1980s by Steven Rosenberg at the National Institutes of Health.

The treatment involves removing the T cells from the tumor, where they have been unable to proliferate. Scientists then take those T cells and grow them outside the body in a lab dish. They treat patients with chemotherapy to kill off the last of their old immune systems. Finally, they reinfuse the lab-grown T cells into the patient’s blood stream and the cells, now in much greater numbers, go on to attack the tumor.

In this treatment, the T cells are often referred to as tumor-infiltrating leukocytes, or TILs.

Kammula said his team has found that tumors shrink partially or completely in about 35 percent of patients who receive the treatment. But they wanted to know why it doesn’t work in the majority of cases, and whether there might be some way to predict beforehand when it will succeed.

To find out, the researchers analyzed samples from 100 different uveal melanoma tumors that had spread to different parts of the body in 84 patients, seeking to examine all of the tumors’ genetic material.

“We basically put the tumor biopsy in a blender that had the stroma [supportive tissue], the blood vessels, the immune cells, the tumor cells. It had everything,” Kammula said, explaining that they then analyzed all of the tumor’s genetic material.

They found 2,394 genes that could have helped make the tumor susceptible to treatment, some of them genes that experts would regard as “the usual suspects” and others that were unexpected. Using this long list of genes, the scientists searched for characteristics that they shared.

The genes were predominantly involved in helping the body defend itself against viruses, bacteria and other foreign invaders by removing the invaders and helping tissue heal. Kammula and the study’s lead author, Shravan Leonard-Murali, a postdoctoral fellow in the lab, used the different activity levels of these genes to develop a clinical tool.

The tool, known as a biomarker, assigns a score to a uveal melanoma tumor based on the likelihood that it will respond well to the treatment ― removing T cells, growing them outside the body, then reinfusing them.

So far, Kammula said, the biomarker has been “extremely good,” in predicting when the treatment will be effective, though he added, “these findings will need confirmation in the current ongoing clinical trial.”

“I thought it was somewhat of a tour de force, honestly,” said Eric Tran, an associate member of the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in Portland, Ore. Tran did not participate in the study.

He said that while it will be important to validate these results, “I was certainly encouraged by their studies. And from my perspective, I wonder if that sort of strategy can be deployed in other cancers.”

Ryan J. Sullivan, an oncologist at Massachusetts General Hospital and associate professor at Harvard Medical School who was not involved in the study, called the team’s work “timely” and said “it is even more significant that they appear to have a [tool] that appears to predict which patients will benefit.”

The team at UPMC is already investigating possible wider application of both the treatment and the biomarker in a second clinical trial that involves a dozen different cancers.

2011, Pulitzer Prize, explanatory reporting

2014, Pulitzer Prize finalist, feature writing

2006, Pulitzer Prize finalist, explanatory reporting

2003 Pulitzer Prize finalist, explanatory reporting

Though The Earth Gives Way

One In A Billion: The Story of Nic Volker and the Dawn of Genomic Medicine 

University of Toronto BA English Literature

Mark Johnson joined The Washington Post in July 2022 after 22 years at The Milwaukee Journal Sentinel, where he covered health and science. He wrote about the first person to survive rabies without vaccine, and reported on the first use of full gene sequencing to diagnose and treat a new disease. 

Mark Johnson

the-washington-post

UPMC and University of Pittsburgh Health Sciences

Space

Animals

Health

Environment

Science

washpost

prism://prism.query/site,/science&limit=20

prism://prism.query/site,/health&limit=20

The Washington Post health section provides coverage and analysis of health, healthcare, nutrition and fitness news.